^
Association details:
| Biomarker: | LRP1B mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The potential biomarkers of checkpoint inhibitor immunotherapy in solid malignancies.
Published date:
05/25/2020
Excerpt:
Eighty-one pts received IO who had NGS sent prior to treatment....Most common gene mutations in CR group were ROS1 (52.6%), LRP1B (52.6%), GRIN2A (47.4%), and EPHA7 (42.1%) in 19 patients.
DOI:
10.1200/JCO.2020.38.15_suppl.e15226
